nach oben

Tumor Biology

Erschienen in:

01.06.2010 | Research Article

RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells

verfasst von: Qin Xu, Xiuming Liu, Yili Cai, Youcheng Yu, Wantao Chen

Erschienen in: Tumor Biology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

A disintegrin and metalloproteinase 9 (ADAM9) is a type I transmembrane protein that has been associated with cancer development and metastases. Here, we show that ADAM9 is highly expressed in metastatic cancer tissues and in an adenoid cystic carcinoma cell line with a high metastatic potential. Using RNA interference for gene silencing, we show that ADAM9 is essential for in vitro cancer cell proliferation and invasion as well as in vivo cancer metastasis in an experimental murine model of lung metastases. These data indicate that ADAM9 is potentially an important new therapeutic target for the prevention of tumor metastases in adenoid cystic carcinoma.

Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, et al. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005;41:328–35.CrossRefPubMed

Hu K, Li SL, Gan YH, Wang CY, Yu GY. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol. 2009;45:156–63.CrossRefPubMed

Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metallprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 2003;54:101–23.CrossRefPubMed

Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140–4.CrossRefPubMed

Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90:369–79.CrossRefPubMed

Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005;65:9312–9.CrossRefPubMed

O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105:754–61.CrossRefPubMed

Fritzsche FR, Jung M, Tölle A, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2008;54:1097–106.CrossRefPubMed

Huang D, Chen W, Zhang Z, Zhang P, He R, Zhou X, et al. Identification of genes with consistent expression alteration pattern in ACC-2 and ACC-M cells by cDNA array. Chin Med J (Engl). 2003;116:448–52.

10.

Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of β-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006;2:31.CrossRef

11.

Xu Q, Zhang Z, Zhang P, Chen W. Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer. 2008;8:159.CrossRefPubMed

12.

Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–3.CrossRefPubMed

13.

Cuneo KC, Fu A, Osusky KL, Geng L. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs. 2007;18:349–55.CrossRefPubMed

14.

Chen J, Peng H, Ou-Yang X, He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res. 2008;18:322–9.CrossRefPubMed

15.

Nakashima Y, Yano M, Kobayashi Y, Moriyama S, Sasaki H, Toyama T, et al. Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Ther. 2003;10:123–30.CrossRefPubMed

16.

Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17–24.PubMed

17.

Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Cancer Res Clin Oncol. 2005;131:41–8.CrossRef

18.

Zheng X, Jiang F, Katakowski M, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 2007;98:674–84.CrossRefPubMed

19.

Rocks N, Estrella C, Paulissen G, et al. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. Cell Prolif. 2008;41:988–1001.CrossRefPubMed

20.

Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. Increase of disintergin metalloprotease 10(ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 2007;245:33–43.CrossRefPubMed

21.

Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 2008;8:179–87.CrossRefPubMed

22.

Boelens MC, Kok K, Van der Vlies P, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer. 2009;66:372–8.CrossRefPubMed

23.

Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer. 2005;116:853–9.CrossRefPubMed

24.

Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005;65:4728–38.CrossRefPubMed

25.

Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190–6.CrossRefPubMed

Titel: RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells
verfasst von: Qin Xu
Xiuming Liu
Yili Cai
Youcheng Yu
Wantao Chen
Publikationsdatum: 01.06.2010
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-010-0034-8

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer

MMP-7 overexpression is an independent prognostic marker in gastric cancer

Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin

Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie